Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 9/20 | 0.48 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | GCKR | Q14397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408554 | 0.86 | CXCR3 (0.48) | CXCR3SGPL1NR1H2NR1H3GCKR | |
| SCHEMBL5480564 | 0.81 | CXCR3 (0.48) | CXCR3SGPL1NR1H2NR1H3GCKR | |
| SCHEMBL6356889 | 0.81 | CXCR3 (0.48) | CXCR3SGPL1NR1H2NR1H3GCKR | |
| SCHEMBL6357386 | 0.81 | CXCR3 (0.48) | CXCR3SGPL1NR1H2NR1H3GCKR | |
| SCHEMBL5748667 | 0.74 | PKM (0.55) | PKMHCRTR1HCRTR2 | |
| SCHEMBL5748862 | 0.74 | CXCR3 (0.46) | CXCR3NR1H2NR1H3GCKR | |
| SCHEMBL5748192 | 0.73 | POLB (0.44) | NR1H2NR1H3HCRTR1HCRTR2CHRM2 | |
| SCHEMBL5795980 | 0.73 | CXCR3 (0.48) | CXCR3NR1H2NR1H3GCKR | |
| SCHEMBL5481910 | 0.72 | PPARG (0.41) | CXCR3HCRTR1HCRTR2 | |
| SCHEMBL5796696 | 0.72 | HCRTR1 (0.54) | PKMHCRTR1HCRTR2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | CXCR3 3739/4885SGPL1 326/4885PKM 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.